Dr. Robert L. Smith JR., M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- Chicago College of Medicine and Surgery (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 88
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Chicago College of Medicine and Surgery
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
FL license ME0074072
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Adventhealth North Pinellas Tarpon Springs, FL
- HCA Florida Trinity Hospital Trinity, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 88
- Services billed
- 175
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 39 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | 50 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 49 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 29 | 23 |
| New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in New Port Richey, FL | 157 |
| Medroxyprogesterone Acetate Other prescribers in New Port Richey, FL | 95 |
| Fluconazole Other prescribers in New Port Richey, FL | 33 |
| Premarin (estrogens, conjugated) Other prescribers in New Port Richey, FL | 32 |
| Metronidazole Other prescribers in New Port Richey, FL | 25 |
| Ibuprofen Other prescribers in New Port Richey, FL | 22 |
| Clobetasol Emollient (clobetasol propionate/emoll) | 21 |
| Progesterone (progesterone, micronized) Other prescribers in New Port Richey, FL | 20 |
| Terconazole | 19 |
| Clotrimazole-Betamethasone (clotrimazole/betamethasone dip) Other prescribers in New Port Richey, FL | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 16 payments worth $380 in total to this clinician.
| Novo Nordisk Inc | $107 |
|---|---|
| Intuitive Surgical, Inc. | $82.33 |
| Astellas Pharma US Inc | $54.38 |
| Millicent US Inc | $45.37 |
| Dexcom, Inc. | $25.34 |
| GlaxoSmithKline, LLC. | $22.15 |
| Corcept Therapeutics | $21.71 |
| Shield Therapeutics Inc | $21.40 |
| Food and Beverage | $380 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $90,201 in research payments for these studies, mostly to the institutions running them.
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
Mylan Inc. · Completed · NCT05139121 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc. · Active, not recruiting · NCT04333576
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.